Signaling execution readiness: The evolving leadership requirements for biotech fundraising.

In a selective global biotech funding environment characterized by a 'flight to quality', startups must signal execution readiness to secure capital. Based on a dataset of Japanese drug discovery startups, we examine how management teams' professional and educational backgrounds relate to fundraising performance, finding stage-dependent patterns. Early-stage startups are predominantly academic-led, yet raise less than those led by pharmaceutical veterans. In later stages, CEOs with purely academic backgrounds are associated with lower funding, whereas CEOs with medical degrees or pharmaceutical experience are associated with higher funding. Retaining academic founder-CEOs early might also introduce governance and conflict-of-interest risks. These results are consistent with a view that leadership should evolve as firms mature-incorporating industry professionals early and, potentially, transitioning founder-CEOs before late-stage transitions.